Hematology

Progression free survival and overall response rate were higher in patients with R/R MM treated with Abecma than those treated with standard of care.

Review top news and interview highlights from the week ending February 10, 2023.

The updated data included a median overall survival of 26 months after treatment with brexu-cel.

The latest data set includes 22 newly evaluable patients with triple-refractory disease.

The POLARIS study adds to the growing body of evidence validating GPRC5D as a target for CAR T-cell therapy in R/R MM.

The FDA cleared Century’s IND for CNTY-101 in August 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The associate professor of medicine from University of Pennsylvania discussed advantages of huCART19-IL18 in NHL and CLL.

Patients treated with ALLO-715 achieved an ORR of 55.8%.

The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.

GC012F recently showed efficacy in newly-diagnosed MM in investigator-initiated trials.

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed updated data on the allogeneic CAR T therapy, UNICART123v1.2.

Review top news and interview highlights from the week ending February 3, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

AB-101 is also being investigated with the innate cell engager AFM13 for CD30 lymphomas.

Positive preclinical data related to SENTI-202 and SENTI-401 were presented at conferences last year.

Sana Biotechnology also plans to submit another IND for the same indications for a CD22-targeted CAR T later in 2022.

Cilta-cel demonstrated a significant improvement in progression-free survival over standards of care.

Review top news and interview highlights from the week ending January 27, 2023.

The chief executive officer and president of Eterna Therapeutics discussed the company’s new collaboration with the University of Texas MD Anderson Cancer Center.

Breyanzi is currently approved for the second-line or later treatment of large B-cell lymphomas.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The CD19/CD20 dual-targeted CAR is currently under investigation in an investigator-initiated study in UCLA.

The dosing of the first patient took place in December 2022 and no adverse events related to the therapy have been reported.

With confidence building, numerous cell and gene therapies will likely go before the FDA and other global regulatory agencies this year, in addition to key data readouts.